Non-Hodgkin's Lymphoma News
Rituxan May Prevent Need for Radiation in Mediastinal B-Cell Lymphoma (May 31, 2013)A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading
RIT Conditioning with Zevalin Prior to Autologous Transplantation Improves Overall Survival in Patients with DLCL (April 5, 2013)Radioimmunotherapy conditioning with Zevalin® (ibritumomab tiuxetan) prior to autologous stem cell transplantation in patients with diffuse large cell lymphoma offers a similar relapse incidence to total body irradiation, but has lower toxicity and improved... Continue Reading
Treanda Plus Rituxan is Not Inferior to R-CHOP and R-CVP for advanced NHL (April 2, 2013)The combination of Treanda® (bendamustine) and Rituxan® (rituximab) was found to be noninferior to the commonly used chemotherapy regimens R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-CVP (rituximab plus cyclophosphamide,... Continue Reading
Zevalin Plus Nonmyeloablative Allogeneic Transplantation Effective in High-Risk B-Cell NHL (March 29, 2013)The addition of Zevalin® (ibritumomab tiuxetan) to nonmyeloablative allogeneic transplantation (NMAT) is safe and produces early responses and prolonged disease control in high-risk patients with B-cell non-Hodgkin’s lymphoma, according to the results... Continue Reading
Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma (March 22, 2013)Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation (ASCT), according to the results of... Continue Reading
Dose-Dense R-CHOP plus Zevalin Improves Response in Diffuse Large B-Cell Lymphoma (March 1, 2013)Dose-dense R-CHOP followed by Zevalin® (ibritumomab tiuxetan) converts partial responses to complete responses and maintains durable responses in patients with untreated diffuse large B-cell lymphoma, according to the results of a study presented at... Continue Reading
Sequential R-CHOP plus Zevalin Shows Promise in High-Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (February 22, 2013)Sequential R-CHOP followed by Zevalin® (ibritumomab tiuxetan) produces encouraging outcomes in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study presented at the 52nd annual meeting of the American Society... Continue Reading
Zevalin Safe and Effective in High-Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (February 15, 2013)Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and effective in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study published in Clinical Cancer Research Non-Hodgkin’s lymphoma... Continue Reading
Cancer Deaths on the Decline (February 11, 2013)Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading
Latest Non-Hodgkin's Lymphoma News By Stage
Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma
Rituxan May Prevent Need for Radiation in Mediastinal B-Cell Lymphoma (May 31, 2013)
A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading
RIT Conditioning with Zevalin Prior to Autologous Transplantation Improves Overall Survival in Patients with DLCL (April 5, 2013)Radioimmunotherapy conditioning with Zevalin® (ibritumomab tiuxetan) prior to autologous stem cell transplantation in patients with diffuse large cell lymphoma offers a similar relapse incidence to total body irradiation, but has lower toxicity and improved... Continue Reading
Treanda Plus Rituxan is Not Inferior to R-CHOP and R-CVP for advanced NHL (April 2, 2013)The combination of Treanda® (bendamustine) and Rituxan® (rituximab) was found to be noninferior to the commonly used chemotherapy regimens R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-CVP (rituximab plus cyclophosphamide,... Continue Reading
Zevalin Plus Nonmyeloablative Allogeneic Transplantation Effective in High-Risk B-Cell NHL (March 29, 2013)The addition of Zevalin® (ibritumomab tiuxetan) to nonmyeloablative allogeneic transplantation (NMAT) is safe and produces early responses and prolonged disease control in high-risk patients with B-cell non-Hodgkin’s lymphoma, according to the results... Continue Reading
Zevalin Plus BEAM Chemotherapy Superior to BEAM Alone in Aggressive Lymphoma (March 22, 2013)Standard-dose Zevalin® (ibritumomab tiuxetan) combined with BEAM high-dose chemotherapy is safe and possibly more effective than BEAM therapy alone as a conditioning regimen for autologous stem cell transplantation (ASCT), according to the results of... Continue Reading
More Aggressive/Intermediate Grade Non-Hodgkin's LymphomaFollicular Lymphoma
Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 8, 2013)
Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading
Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (February 1, 2013)Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according... Continue Reading
Zevalin Effective in Follicular NHL Refractory to Rituximab (January 24, 2013)Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical... Continue Reading
Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma (January 10, 2013)Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with advanced follicular lymphoma, according to the... Continue Reading
Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading
More Follicular LymphomaHighly Aggressive/High Grade Non-Hodgkin's Lymphoma
Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)
Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading
Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading
Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading
Children and Teens Have Better NHL Survival than Young Adults (March 15, 2010)Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s... Continue Reading
New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology (March 8, 2009)New and Novel Agents for the Treatment of Non-Hodgkin’s Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin’s... Continue Reading
More Highly Aggressive/High Grade Non-Hodgkin's LymphomaIndolent/Low Grade Non-Hodgkin's Lymphoma
Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (February 8, 2013)
Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading
Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (February 1, 2013)Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according... Continue Reading
Zevalin Effective in Follicular NHL Refractory to Rituximab (January 24, 2013)Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical... Continue Reading
Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma (January 10, 2013)Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with advanced follicular lymphoma, according to the... Continue Reading
Several Effective Treatment Options for Early Follicular Lymphoma (September 4, 2012)The results of a recent study published in the Journal of Clinical Oncology challenge the standard treatment approach for follicular lymphoma—indicating that with proper staging at diagnosis, there are several treatment regimens that can bring a remission. Non-Hodgkin’s... Continue Reading
More Indolent/Low Grade Non-Hodgkin's LymphomaMantle Cell Non-Hodgkin's Lymphoma
R-CHOP Induction Plus Rituxan Maintenance Improves Remission in Older Patients with Mantle Cell Lymphoma (October 23, 2012)
Induction therapy with R-CHOP followed by maintenance with Rituxan® (rituximab) nearly doubled the remission duration in older patients with mantle cell lymphoma, according to the results of a study published in the New England Journal of Medicine. Non-Hodgkin’s... Continue Reading
Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading
Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading
Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading
Children and Teens Have Better NHL Survival than Young Adults (March 15, 2010)Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s... Continue Reading
More Mantle Cell Non-Hodgkin's LymphomaRecurrent Non-Hodgkin's Lymphoma
Adcetris Approved for Two Types of Lymphoma (August 26, 2011)
The targeted therapy Adcetris™ (brentuximab vedotin) has received accelerated approved by the US Food and Drug Administration (FDA) for the treatment of two types of lymphoma: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Hodgkin... Continue Reading
Brentuximab Vedotin Effective for Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma (June 16, 2011)Researchers involved in an international multicenter trial have reported that brentuximab vedotin was effective for treatment of patients with relapsed or refractory anaplastic large cell lymphoma. The details of this study were reported at the 2011 meeting... Continue Reading
Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading
Survivors of Some Childhood Cancers May Face Cognitive Impairment (May 18, 2010)Survivors of non-central nervous system (CNS) childhood cancers reported a statistically and clinically significantly higher rate of neurocognitive impairment than their cancer-free siblings, according to the results of a study published in the Journal... Continue Reading
Children and Teens Have Better NHL Survival than Young Adults (March 15, 2010)Even after accounting for stage at diagnosis and subtype of non-Hodgkin’s lymphoma (NHL), children and teens with NHL have better survival than young adults with NHL. These results were published in the Archives of Pediatrics and Adolescent Medicine. Non-Hodgkin’s... Continue Reading
More Recurrent Non-Hodgkin's LymphomaScreening/Prevention Non-Hodgkin's Lymphoma
Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)
A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading
Organ Transplant Recipients Have Increased Cancer Risk (November 9, 2011)People who have received a solid organ transplant (such as a kidney or liver) are twice as likely as people in the general population to develop cancer. These results were published in the Journal of the American Medical Association. In 2010, more than... Continue Reading
Greater Cancer Risk Among Taller Women (July 28, 2011)Taller women may have an increased risk of developing certain cancers. Overall, cancer risk increases by 16% for every 4-inch increase in height. These findings were recently reported in Lancet Oncology. Greater insight into height and cancer risk may... Continue Reading
Stay on Top of Your Family History of Cancer (July 15, 2011)People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading
Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading
More Screening/Prevention Non-Hodgkin's LymphomaT-Cell Non-Hodgkin's Lymphoma
Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)
The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading
Lymphoma During Pregnancy Can Have Good Outcomes (March 14, 2012)Among women who are diagnosed with lymphoma during pregnancy, the outcomes for both mother and baby are often good. This was true for women who began lymphoma treatment during the second or third trimester of pregnancy, as well as women who deferred treatment... Continue Reading
Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading
Folotyn Benefits Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (February 3, 2011)In the Phase II PROPEL study, 29% of patients with relapsed or refractory peripheral T-cell lymphoma (a type of non-Hodgkin’s lymphoma) experienced a complete or partial disappearance of detectable cancer following treatment with Folotyn® (pralatrexate).... Continue Reading
Istodax Active against Refractory Cutaneous T-cell Lymphoma (August 31, 2010)Final results from a Phase II clinical trial provide additional evidence that Istodax® (romidepsin) is active against refractory cutaneous T-cell lymphoma. These results were published in the Journal of Clinical Oncology. Cutaneous T-cell lymphoma (CTCL)... Continue Reading
More T-Cell Non-Hodgkin's Lymphoma